VIP152是一种选择性CDK9抑制剂,在慢性淋巴细胞白血病中具有临床前体外和体内疗效
VIP152在100 nM时主要抑制CDK9,效力比其他在研抑制剂高10倍以上;它可诱导CLL细胞系和原代患者样本细胞死亡,机制涉及干扰P-TEFb组装及ARE失调的RNA降解;在Eµ-MTCP1过表达小鼠模型中,VIP152较溶媒组降低疾病负荷并改善总生存。
要点
- VIP152在100 nM时主要抑制CDK9,效力较其他在研抑制剂高10倍以上。
- VIP152可诱导CLL细胞系和原代患者样本细胞死亡。
- 在Eµ-MTCP1过表达小鼠模型中,VIP152较溶媒组降低疾病负荷并改善总生存。
核心结论
- VIP152是高度选择性CDK9抑制剂,可能成为CLL有吸引力的新疗法。
研究设计与样本
- 临床前体外和体内研究,使用CLL细胞系、原代患者样本及Eµ-MTCP1过表达小鼠模型。
主要发现
- VIP152在100 nM时主要抑制CDK9,效力比其他在研抑制剂高10倍以上。
- VIP152诱导CLL细胞系和原代患者样本细胞死亡。
- 转录组分析显示VIP152通过AU富集元件(ARE)失调抑制RNA降解。
- 机制上,VIP152抑制P-TEFb组装到转录机器并干扰结合伴侣。
- 在Eµ-MTCP1过表达小鼠模型中,VIP152较溶媒组降低疾病负荷并改善总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor complex (P-TEFb), a heterodimeric protein complex composed of cyclin dependent kinase 9 (CDK9) and cyclin T1, functions to regulate short half-life transcripts by phosphorylation of RNA Polymerase II (POLII). These transcripts are frequently dysregulated in hematologic malignancies; however, therapies targeting inhibition of P-TEFb have not yet achieved approval for cancer treatment. VIP152 kinome profiling revealed CDK9 as the main enzyme inhibited at 100 nM, with over a 10-fold increase in potency compared with other inhibitors currently in development for this target. VIP152 induced cell death in CLL cell lines and primary patient samples. Transcriptome analysis revealed inhibition of RNA degradation through the AU-Rich Element (ARE) dysregulation. Mechanistically, VIP152 inhibits the assembly of P-TEFb onto the transcription machinery and disturbs binding partners. Finally, immune competent mice engrafted with CLL-like cells of Eµ-MTCP1 over-expressing mice and treated with VIP152 demonstrated reduced disease burden and improvement in overall survival compared to vehicle-treated mice. These data suggest that VIP152 is a highly selective inhibitor of CDK9 that represents an attractive new therapy for CLL.
引用
- Sher S, Whipp E, Walker J, et al. VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2022. PMID: 36376377. doi:10.1038/s41375-022-01758-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。